United States
Print page content Print
Increase text size Decrease text size
Text Size
Apoquel Logo

APOQUEL® is proven to provide fast, effective, long-term relief

Effective in a variety of allergic skin diseases
Fast itch relief
Provides significant long-term relief

Atopica is a registered trademark of Eli Lilly and Company, its subsidiaries and affiliates.

Indications
Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

Important Safety Information
Do not use APOQUEL in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.

For more information, please see the full Prescribing Information.

References: 1. Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013;24(5):479-e114. doi:10.1111/vde.12047. 2. Moriello KA. Canine allergic dermatitis: pathogenesis, clinical signs, and diagnosis. http://veterinarymedicine.dvm360.com/canine-allergic-dermatitis-pathogenesis-clinical-signs-and-diagnosis. Accessed November 3, 2016. 3. Gadeyne C, Little P, King VL, et al. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014;25(6):512-518. doi:10.1111/vde.12166. 4. Little PR, King VL, Davis KR, et al. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and cyclosporine for the control of atopic dermatitis in client-owned dogs. Vet Dermatol. 2015;26(1):23-30. doi:10.1111/vde.12186. 5. Cosgrove SB, Cleaver DM, King VL, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol. 2015;26(3):171-179. doi:10.1111/vde.12194.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.

© 2017 Zoetis Services LLC. All rights reserved. APQ-00371